Affymetrix and IPSOGEN Collaborate to Develop and Market In-Vitro Diagnostic Cancer Tests

SANTA CLARA, Calif.—(BUSINESS WIRE)—Aug. 28, 2007—Affymetrix Inc. (Nasdaq: AFFX) and IPSOGEN, a leading molecular diagnostic company based in France and Connecticut, today announced that they have signed a Powered by Affymetrix(TM) (PbA) agreement. With this agreement, IPSOGEN gains non-exclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic (IVD) tests, initially for breast cancer, on a worldwide basis.

Source: Affymetrix, Inc.